Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2017 | 1 |
2018 | 1 |
2022 | 2 |
2023 | 3 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
A plain language summary of what clinical studies can tell us about the safety of evobrutinib - a potential treatment for multiple sclerosis.
Neurodegener Dis Manag. 2023 Aug;13(4):207-213. doi: 10.2217/nmt-2023-0003. Epub 2023 Jun 22.
Neurodegener Dis Manag. 2023.
PMID: 37345645
Free article.
Review.
Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis.
Montalban X, Wallace D, Genovese MC, Tomic D, Parsons-Rich D, Le Bolay C, Kao AH, Guehring H.
Montalban X, et al. Among authors: parsons rich d.
J Neurol Neurosurg Psychiatry. 2023 Jan;94(1):1-9. doi: 10.1136/jnnp-2022-328799. Epub 2022 Nov 23.
J Neurol Neurosurg Psychiatry. 2023.
PMID: 36418156
Free PMC article.
Clinical Trial.
Item in Clipboard
Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial.
Wallace DJ, Dörner T, Pisetsky DS, Sanchez-Guerrero J, Patel AC, Parsons-Rich D, Le Bolay C, Drouin EE, Kao AH, Guehring H, Dall'Era M.
Wallace DJ, et al. Among authors: parsons rich d.
ACR Open Rheumatol. 2023 Jan;5(1):38-48. doi: 10.1002/acr2.11511. Epub 2022 Dec 18.
ACR Open Rheumatol. 2023.
PMID: 36530019
Free PMC article.
Item in Clipboard
Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study.
Schmieder GJ, Draelos ZD, Pariser DM, Banfield C, Cox L, Hodge M, Kieras E, Parsons-Rich D, Menon S, Salganik M, Page K, Peeva E.
Schmieder GJ, et al. Among authors: parsons rich d.
Br J Dermatol. 2018 Jul;179(1):54-62. doi: 10.1111/bjd.16004. Epub 2018 Mar 6.
Br J Dermatol. 2018.
PMID: 28949012
Clinical Trial.
Item in Clipboard
Phase 1 dose-escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXaI16L ).
Parsons-Rich D, Hua F, Li G, Kantaridis C, Pittman DD, Arkin S.
Parsons-Rich D, et al.
J Thromb Haemost. 2017 May;15(5):931-937. doi: 10.1111/jth.13673. Epub 2017 Apr 25.
J Thromb Haemost. 2017.
PMID: 28294526
Free article.
Clinical Trial.
Item in Clipboard
Cite
Cite